ER+ Breast Cancer Clinical Trials

9 recruiting

ER+ Breast Cancer Trials at a Glance

9 actively recruiting trials for er+ breast cancer are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 2 with 8 trials, with the heaviest enrollment activity in New York, Salt Lake City, and Boston. Lead sponsors running er+ breast cancer studies include Royal Marsden NHS Foundation Trust, Jacobio Pharmaceuticals Co., Ltd., and Forward Pharmaceuticals Co., Ltd..

Browse er+ breast cancer trials by phase

Treatments under study

About ER+ Breast Cancer Clinical Trials

Looking for clinical trials for ER+ Breast Cancer? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new ER+ Breast Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about ER+ Breast Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 2

Circulating Tumor DNA

ER+ Breast Cancer
Yale University50 enrolled7 locationsNCT06923527
Recruiting
Phase 2

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer

Breast CancerMetastatic Breast CancerMetastatic Breast Carcinoma+2 more
Memorial Sloan Kettering Cancer Center46 enrolled8 locationsNCT05534438
Recruiting
Phase 1Phase 2

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

Breast CancerOvarian CancerEndometrial Cancer+8 more
858 Therapeutics, Inc.120 enrolled14 locationsNCT06395519
Recruiting
Phase 1Phase 2

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Metastatic Breast CancerHER2-negative Breast CancerAdvanced Breast Cancer+1 more
RayzeBio, Inc.124 enrolled31 locationsNCT06590857
Recruiting
Phase 1Phase 2

JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

Solid TumorsER+ Breast Cancer
Jacobio Pharmaceuticals Co., Ltd.102 enrolled8 locationsNCT05490472
Recruiting
Phase 1Phase 2

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

Metastatic Breast CancerBreast Cancer Stage IBreast Cancer Stage II+2 more
Forward Pharmaceuticals Co., Ltd.196 enrolled1 locationNCT07002177
Recruiting
Not Applicable

Breast Re-irradiation After Second Ipsilateral Lumpectomy

Breast CancerCancer of the BreastHER2-negative Breast Cancer+2 more
Youssef Zeidan114 enrolled2 locationsNCT06867484
Recruiting
Phase 2

A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer

HER2-negative Breast CancerER+ Breast Cancer
Royal Marsden NHS Foundation Trust1,100 enrolled49 locationsNCT04985266
Recruiting
Phase 2

Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression

Metastatic Breast CancerAdvanced Breast CancerER+ Breast Cancer
Royal Marsden NHS Foundation Trust324 enrolled18 locationsNCT04920708